Name (Synonyms) | Correlation | |
---|---|---|
drug1260 | Home Sleep Apnea Testing or In-hospital Polysomnography Wiki | 1.00 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D001049 | Apnea NIH | 1.00 |
D020181 | Sleep Apnea, Obstructive NIH | 0.58 |
D012891 | Sleep Apnea, NIH | 0.50 |
D011014 | Pneumonia NIH | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002104 | Apnea HPO | 1.00 |
HP:0002870 | Obstructive sleep apnea HPO | 0.58 |
HP:0010535 | Sleep apnea HPO | 0.50 |
HP:0002090 | Pneumonia HPO | 0.06 |
There is one clinical trial.
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
Description: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)
Measure: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion Time: 48 hoursDescription: Alive and not intubated 28 days after the date of first infusion
Measure: 28-day treatment success, defined as S28 Time: 28 daysDescription: Time to extubation
Measure: Time to extubation Time: 28 daysDescription: Oxygenation requirement (PaO2/FiO2) change between day 0 and day +11
Measure: Oxygenation improvement Time: 11 daysDescription: Ventilator free days measured at day 28
Measure: Ventilator free days Time: 28 daysDescription: Organ failure free days measured at day 28
Measure: Organ failure free days Time: 28 daysDescription: ICU free days measured at day 28
Measure: ICU free days Time: 28 daysDescription: All-cause mortality at day 28
Measure: All-cause mortality Time: 28 days